← Scroll for more →
Financial Statements — GMHS
Balance Sheet
(in millions USD)| Metric | Q4 2026 | Q4 2025 | Q3 2025 | Q4 2024 |
|---|---|---|---|---|
| Cash & Equivalents | 17.57 | 15.23 | 15.70 | 18.82 |
| Short-term Investments | 5.10 | 1.35 | -- | -- |
| Accounts Receivable | 8.04 | 10.42 | 11.35 | 11.02 |
| Total Current Assets | 42.43 | 39.57 | 41.90 | 41.59 |
| Property, Plant & Equipment | 0.88 | 0.12 | 0.11 | 0.13 |
| Intangible Assets | 3.52 | 5.00 | 4.81 | 5.29 |
| Total Non-current Assets | 12.71 | 7.63 | 7.34 | 9.69 |
| Total Assets | 55.14 | 47.21 | 49.24 | 51.28 |
| Accounts Payable | 11.44 | 10.75 | 13.67 | 0.56 |
| Short-term Debt | 0.76 | -- | -- | -- |
| Total Current Liabilities | 14.95 | 14.04 | 18.03 | 16.88 |
| Total Non-current Liabilities | 1.53 | 0.06 | 0.01 | 0.35 |
| Total Liabilities | 16.49 | 14.10 | 18.04 | 17.24 |
| Retained Earnings | 27.83 | 23.54 | 21.96 | 19.58 |
| Total Stockholder Equity | 39.20 | 33.23 | 31.23 | 34.02 |
← Scroll for more columns →
Income Statement
(in millions USD) (except per-share rows)| Metric | Q3 2025 |
|---|---|
| Total Revenue | 87.39 |
| Cost of Revenue | 41.36 |
| Gross Profit | 46.03 |
| Research & Development | 4.25 |
| Selling, General & Admin | 3.14 |
| Total Operating Expenses | 44.02 |
| Operating Income | 2.01 |
| Pretax Income | 2.48 |
| Tax Provision | 0.17 |
| Net Income | 2.38 |
| Basic EPS | 0.04 |
| Diluted EPS | 0.04 |
← Scroll for more columns →
Cash Flow Statement
(in millions USD)| Metric | Q3 2025 |
|---|---|
| Operating Cash Flow | 0.76 |
| Capital Expenditures | 0.02 |
| Free Cash Flow* | 0.74 |
| Investing Cash Flow | (0.23) |
| Financing Cash Flow | (3.68) |
← Scroll for more columns →
* Derived from reported values